Compassionate medicine schemes help patients with cancer live better and for longer — why are they not more widely used? Use of unlicensed or off-label medicines for patients with cancer can extend survival or improve quality of life, but access remains patchy.…
The role of circulating tumour DNA in guiding cancer treatment and future applications An overview of current and future applications of circulating tumour DNA in common solid tumours and the implications on treatment.…
Immune-related cancer toxicities: what pharmacists need to know In this episode of The PJ Pod, we explore the side effects of cancer immunotherapy and consider what pharmacists can do to support patients throughout the course of their treatment.… Supported content
Renal cancer: management An overview of the most common forms of renal cancer, treatment options and the role of pharmacists in its management.… Supported content
Bladder cancer: management An overview of the different types of bladder cancer, treatment options and the role of pharmacists in its management.… Supported content
Break in cancer treatment cuts side effects and does not affect life expectancy, study finds A trial has shown that breaks from first-line treatments for patients with metastatic and/or locally advanced kidney cancer did not cause meaningful detriment to their life expectancy or quality of life.…
Cervical cancer prevention: advice and services With the uptake of cervical screening at 70–73% in the UK, it is important for pharmacy teams to recognise the symptoms of cervical cancer, as well as provide advice on prevention strategies.…
Implementing chimeric antigen receptor T-cell therapy in practice How pharmacists can ensure the safe delivery of chimeric antigen receptor T-cell therapy by ensuring governance, operational and clinical requirements are met.…
Going against type: the new class of cancer therapies targeting mutations rather than tissues ‘Tumour agnostic’ drugs offer a more effective and tolerable therapy for a wide range of people with cancer, so why has the NHS rejected its first one?…
The precision medicine approach to cancer therapy: part 2 — haematological malignancies An overview of the anticancer agents that have been approved for use in the UK as part of a precision medicine approach for haematological malignancies, along with information relating to the relevant biomarkers and biomarker assays currently available. …
